amplification induces sensitivity to anti therapy in pancreatic acinar cell carcinoma.

Fiche publication

Date publication

avril 2018

Journal

World journal of gastrointestinal oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOIDOT Romain , Pr GHIRINGHELLI François

Tous les auteurs :
Richard C, Niogret J, Boidot R, Ghiringhelli F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29666669

Résumé

Pancreatic acinar cell carcinoma (PACC) is a rare cancer. When the tumor is metastatic, few therapeutic options are available. Precision medicine using next-generation sequencing is defined by the administration of drugs based on the tumor genetic mutations. The usage of precision medicine for finding new therapeutic options for rare cancers is an emerging field. We have reported here the case of a patient bearing a multitreated metastatic PACC. This patient underwent somatic and constitutional exome analyses. The analyses revealed in the liver metastasis an amplification of the gene. Accordingly, the patient was treated with off-label usage of panitumumab. We observed rapid response with necrosis of the liver metastasis, while no efficacy was observed in the primary tumor. An exome analysis of the primary tumor revealed amplification of and with amplification. Such amplifications are known as a resistance mechanism to anti therapy. Our results suggest that exome analysis may be helpful to highlight targets in rare cancers, such as PACC. amplification in this pathology should be determined and could be used as a biomarker to propose anti therapy.